depemokimab
Selected indexed studies
- Twice-Yearly Depemokimab in Severe Asthma with an Eosinophilic Phenotype. (N Engl J Med, 2024) [PMID:39248309]
- Efficacy and safety of twice per year depemokimab in chronic rhinosinusitis with nasal polyps (ANCHOR-1 and ANCHOR-2): phase 3, randomised, double-blind, parallel trials. (Lancet, 2025) [PMID:40037388]
- Depemokimab, the first ultra-long-acting anti-IL-5 monoclonal antibody for severe eosinophilic asthma. (Med, 2024) [PMID:39674169]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Twice-Yearly Depemokimab in Severe Asthma with an Eosinophilic Phenotype. (2024) pubmed
- Efficacy and safety of twice per year depemokimab in chronic rhinosinusitis with nasal polyps (ANCHOR-1 and ANCHOR-2): phase 3, randomised, double-blind, parallel trials. (2025) pubmed
- Depemokimab, the first ultra-long-acting anti-IL-5 monoclonal antibody for severe eosinophilic asthma. (2024) pubmed
- Switching to twice-yearly depemokimab from mepolizumab/benralizumab in severe asthma: a multicenter, randomized, double-blind, phase 3A clinical trial (NIMBLE). (2026) pubmed
- Depemokimab. (2006) pubmed
- Depemokimab: a new long-acting anti-IL5 treatment for severe asthma and chronic rhinosinusitis with nasal polyps. (2025) pubmed
- Safety and Tolerability of Twice-Yearly Depemokimab in Patients with Asthma and Chronic Rhinosinusitis with Nasal Polyps: Pooled Results from SWIFT-1/-2 and ANCHOR-1/-2. (2026) pubmed
- Depemokimab: First Approval. (2026) pubmed
- World Health Organization and International Consensus Classification of eosinophilic disorders: 2024 update on diagnosis, risk stratification, and management. (2024) pubmed
- Depemokimab in chronic rhinosinusitis with nasal polyps: A turning point or a missed opportunity? (2025) pubmed